After more than 40 years of accumulation, the development of Nucleic Acid Therapeutics has experienced ups and downs. With the continuous breakthroughs in related technologies, it has gradually emerged from the downturn and ushered in the harvest era. As a disruptive innovative therapy, Nucleic Acid Therapeutics have been widely used in the treatment of Genetic Diseases, Tumors, Cardiovascular Diseases, Viral Infections and other diseases, and have gradually shown increasing potential. From the proposal of the concept of antisense nucleic acid in 1978 to the approval of the world's first ASO drug by the FDA in 1998, as of the end of 2023, there are currently 19 Small Nucleic Acid Drugs on the market worldwide. Among them, there was an outbreak in 2023, with a total of 4 Small Nucleic Acid Drugs launched. At the same time, the treatment direction has gradually transitioned from rare diseases to common diseases such as liver-related cardiovascular and metabolic diseases. With the launch of the first long-acting lipid lowering siRNA drug-Novartis's Inclisiran in 2020, Small Nucleic Acid Drugs have shown great prospects in the field of chronic diseases.

At the same time, mRNA technology has entered a rapid development stage under the COVID-19 pandemic. In addition to the various COVID-19 mRNA vaccines approved for marketing, mRNA technology has made important progress in the fields of RSV Vaccines, Influenza Vaccines, and Therapeutic Cancer Vaccines. In addition, mRNA technology has great potential for application in Protein Replacement Therapy, Cell therapy and Gene editing, Regenerative Medicine and other fields.

In view of this, the xRNA Therapeutics Development and Innovation Forum will invite and bring together experts and scientists from the innovative Nucleic Acid Vaccine and Therapeutics Companies, leading Research Institutions to strengthen exchanges and cooperation, focusing on mRNA/circRNA Vaccines and Therapeutics, Oligonucleotide Therapy from Early Research, Preclinical and Clinical Development to Delivery Technology, Process Development and Manufacturing Sciences. 

Conference Major Sessions/Topics

• Progress, Frontier, Innovation and Cooperation for The Nucleic Acid Drug Industry
• mRNA/circRNA Vaccine and Therapeutics Development, Preclinical and Clinical Research
• mRNA/circRNA Process Development and Production, Analysis and Quality Control
• mRNA/circRNA Cancer Vaccine and Cancer Immunotherapy Development
• mRNA/circRNA-based Advanced Therapies (Cell Therapy and Gene Editing etc.)
• Oligonucleotide Drug Development, Preclinical and Clinical Research
• Oligonucleotide Process Development and Production, Analysis and Quality Control
• Nucleic Acid Drug Delivery Technology Innovation and Translation
• Investment and Financing of the Nucleic Acid Drug Industry

Currently we are receiving the podium/poster abstracts. If you are working in the above areas, you are invited to submit a proposal.

For more information, please contact:

Wei Zhang
Program Manager
Organizing Committee
Email: wzhang@deliver-consulting.com
Phone: 86-21-5269-8916